Using a ketogenic diet to treat Alzheimer's disease
The Ketogenic Diet for Alzheimer's Disease: a Randomized Controlled Feasibility Study.
NA · Assistance Publique - Hôpitaux de Paris · NCT04701957
This study is testing if a ketogenic diet can help improve memory and thinking skills in people aged 50 and older with early onset Alzheimer's disease.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 70 (estimated) |
| Ages | 50 Years and up |
| Sex | All |
| Sponsor | Assistance Publique - Hôpitaux de Paris (other) |
| Locations | 1 site (Paris) |
| Trial ID | NCT04701957 on ClinicalTrials.gov |
What this trial studies
This study investigates the effects of a ketogenic diet on patients with early onset Alzheimer's disease. The ketogenic diet aims to shift the brain's energy source from glucose to ketone bodies, which may help reduce neuroinflammation and improve cognitive function. Participants will be monitored for changes in memory, executive function, and overall cognitive health while adhering to the diet. The study includes individuals aged 50 and older who have confirmed Alzheimer's disease and are able to communicate in French.
Who should consider this trial
Good fit: Ideal candidates are individuals aged 50 and older with confirmed Alzheimer's disease and a caregiver present.
Not a fit: Patients with diabetes, other neurological diseases, or severe chronic conditions may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could provide a novel dietary intervention to slow cognitive decline in Alzheimer's patients.
How similar studies have performed: While the ketogenic diet has shown promise in animal models and in treating epilepsy, evidence in Alzheimer's disease is still limited and this approach is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age \>= 50 * AD confirmed by biomarkers (CSF and/or PET scan) * CDR score=0.5 or 1 * Speaking/understanding French * Presence of a caregiver Exclusion Criteria: * Diabetes * Other neurological disease * Chronic inflammatory disease or anti-inflammatory medication (e.g. NSAI, corticosteroids) * Uncontrolled dyslipidemia * Malnutrition (BMI \< 18; or weight loss \> 5% in 1 month or 10% in 6 months; or MNA \< 17) * Severe chronic condition or organ dysfunction
Where this trial is running
Paris
- Cognitive Neurology Center - Lariboisière Fernand Widal University Hospital (APHP) — Paris, France (RECRUITING)
Study contacts
- Study coordinator: LILAMAND Matthieu, MD PhD
- Email: matthieu.lilamand@aphp.fr
- Phone: +33140054954
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Alzheimer Disease, Early Onset